Sunday, April 12, 2026 – A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due

Saturday, April 11, 2026 – Saturday, April 11 – More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not

Friday, April 10, 2026 – Saturday, April 11 – (MedPage Today) — GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men

Friday, April 10, 2026 – Saturday, April 11 – Here’s everything we know so far.

Friday, April 10, 2026 – Saturday, April 11 – New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed

Friday, April 10, 2026 – Friday, April 10 – By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular

Friday, April 10, 2026 – Friday, April 10 – → A decorated GLP-1 pioneer is retiring at Novo Nordisk.

Channeling Elvis Presley with a microphone emoji for good measure,

Friday, April 10, 2026 – Friday, April 10 – Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.

Thursday, April 9, 2026 – Friday, April 10 – Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less,

Thursday, April 9, 2026 – Friday, April 10 – (MedPage Today) — Integrating the most effective obesity treatments into cancer survivorship offers “an unprecedented opportunity” to improve long-term outcomes in

Thursday, April 9, 2026 – Friday, April 10 – The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout

Thursday, April 9, 2026 – Friday, April 10 – Steve Ubl, chief executive of PhRMA, plans to step down at the end of the ‌year, after more than a decade

Wednesday, April 8, 2026 – Thursday, April 9 – 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight

Wednesday, April 8, 2026 – Thursday, April 9 – Changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs — and whether the

Wednesday, April 8, 2026 – Thursday, April 9 –

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — In a whistleblower lawsuit, a prominent cardiologist says he was fired from the University of Pittsburgh Medical Center

Tuesday, April 7, 2026 – Wednesday April 8 – (MedPage Today) — Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in

Tuesday, April 7, 2026 – Wednesday April 8 – Plus, news about Vertex and Halozyme, Werewolf, and Regeneron:

Novo Nordisk launches high-dose Wegovy in the US: The 7.2 mg

Tuesday, April 7, 2026 – Wednesday April 8 – Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout

Tuesday, April 7, 2026 – Wednesday April 8 – The FDA has approved a new once-daily GLP-1 pill for weight loss. Image Credit: Healthline/Photo by Eli Lilly

Federal regulators have

Monday, April 6, 2026 – MONDAY, April 6, 2026 — Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight

Monday, April 6, 2026 – Tuesday, April 7 – Combat muscle loss with this 7-move routine.

Monday, April 6, 2026 – Tuesday, April 7 – Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or

Monday, April 6, 2026 – Tuesday, April 7 – Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into

Saturday, April 4, 2026 – Sunday, April 5 – (MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns

Thursday, April 2, 2026 – Friday, April 3 – PLAINSBORO, NJ and BAGSVÆRD, Denmark, April 2, 2026 /PRNewswire/ — Novo Nordisk will present the ORION study at the upcoming Obesity

Thursday, April 2, 2026 – Friday, April 3 – Their effectiveness also depends on what else you do when you take them.

Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — A popular weight loss drug may soon be more affordable for some people.
Danish pharmaceutical company Novo Nordisk has

Thursday, April 2, 2026 – THURSDAY, April 2, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to

Thursday, April 2, 2026 – Friday, April 3 – A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis

Thursday, April 2, 2026 – Friday, April 3 – (MedPage Today) — As a primary care physician and obesity board-certified specialist, I believe that GLP-1s are one of the best

Thursday, April 2, 2026 – Friday, April 3 – Potential import tariffs on drugs, Foundayo is here-o, and other biotech news from The Readout

Wednesday, April 1, 2026 – Thursday, April 2 – Eli Lilly and Co. anticipates shipping newly approved Foundayo (orforglipron) within the next week, as the drug becomes the second oral

Wednesday, April 1, 2026 – Thursday, April 2 – Wegovy (semaglutide) has passed the notoriously strict cost-effectiveness scrutiny of the U.K. health technology assessment body and will now be reimbursed

Wednesday, April 1, 2026 – Thursday, April 2 – Physical activity is crucial when you’re taking this medication.

Wednesday, April 1, 2026 – Thursday, April 2 – (MedPage Today) — The FDA has approved a second oral GLP-1 receptor agonist for weight loss in adults with obesity or

Wednesday, April 1, 2026 – Thursday, April 2 – Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version

Wednesday, April 1, 2026 – WEDNESDAY, April 1, 2026 — For adults with type 2 diabetes (T2D) who were not achieving glycemic control while receiving a stable dose of dulaglutide,

Wednesday, April 1, 2026 – Thursday, April 2 – Now Eli Lilly has an obesity pill, too.

On Wednesday, the FDA approved orforglipron, the agency announced. It will be

Wednesday, April 1, 2026 – Thursday, April 2 – Microdosing GLP-1 drugs is trending on social media and supported by some doctors, but experts warn the practice lacks a standard

Wednesday, April 1, 2026 – Thursday, April 2 – Now Eli Lilly has an obesity pill, too.

On Wednesday, the FDA approved orforglipron, the agency announced. It will be

Wednesday, April 1, 2026 – Thursday, April 2 – While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.

Tuesday, March 31, 2026 – Wednesday, April 1 – INDIANAPOLIS, March 28, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase

Tuesday, March 31, 2026 – Wednesday, April 1 – PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ — Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides

Tuesday, March 31, 2026 – Wednesday, April 1 – (MedPage Today) — GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes,

Tuesday, March 31, 2026 – TUESDAY, March 31, 2026 — For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk

Tuesday, March 31, 2026 – Wednesday, April 1 – (MedPage Today) — The PREVENT-TAHA8 intracoronary stem cell trial from Iran was officially retracted by The BMJ, months after an expression

Tuesday, March 31, 2026 – Wednesday, April 1 – (MedPage Today) — A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events

Tuesday, March 31, 2026 – Wednesday, April 1 – A nascent biotech in the suburbs of Denver has convinced investors to commit $100 million to develop an oral small molecule

Tuesday, March 31, 2026 – Wednesday, April 1 – Novo Nordisk is unveiling a subscription model for self-pay customers of its popular GLP-1 weight loss drug Wegovy with much lower

Tuesday, March 31, 2026 – Tuesday, March 31 – You can now pay for Wegovy shots and pills just like you pay for an Amazon Prime subscription.

Novo Nordisk

Monday, March 30, 2026 – Tuesday, March 31 – (MedPage Today) — DENVER — Adding a GLP-1 agonist to psoriasis medication significantly improved outcomes in patients with psoriatic arthritis (PsA)

Monday, March 30, 2026 – Tuesday, March 31 – An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide

Monday, March 30, 2026 – Tuesday, March 31 – Researchers at the Institute for Bioengineering of Catalonia (IBEC) have produced a mutational map showing how mutations in amylin—a hormone that

Monday, March 30, 2026 – Monday, March 30 – Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic

Monday, March 30, 2026 – Monday, March 30 – US firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministersBusiness live – latest

Sunday, March 29, 2026 – Sunday, March 29 – Photo Illustration by Thomas Levinson/The Daily Beast/BravoThe Real Housewives of Salt Lake City is TV’s best soap opera, week after week

Sunday, March 29, 2026 – Sunday, March 29 – Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that targets four

Sunday, March 29, 2026 – Sunday, March 29 – GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they’re not improving a critical measure of

Sunday, March 29, 2026 – Sunday, March 29 – Ozempic’s weight loss benefits might come at the cost of muscle strength, even if muscle size remains relatively stable. This raises

Sunday, March 29, 2026 – Scientists are racing to improve weight loss treatments beyond drugs like Ozempic and Wegovy, which are effective but plagued by nausea, bone loss, and weight

Sunday, March 29, 2026 – GLP-1s can be a game changer, but lifestyle habits are still important.

Sunday, March 29, 2026 – Some people taking Ozempic, Wegovy, or Mounjaro notice that food suddenly tastes sweeter or saltier, and this subtle shift in flavor perception appears tied to

Sunday, March 29, 2026 – Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20%

Sunday, March 29, 2026 – Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk

Sunday, March 29, 2026 – Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may

Sunday, March 29, 2026 – Audience: Consumer PLAINSBORO, NJ, December 5, 2025 – FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of

Sunday, March 29, 2026 – Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive

Sunday, March 29, 2026 – Bariatric surgery far outperformed GLP-1 weight loss drugs in a new real-world comparison of more than 50,000 patients. Two years after treatment, surgery patients lost

Sunday, March 29, 2026 – Audience: Health Care Professional, Consumer January 13, 2026

FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of

Sunday, March 29, 2026 – Popular weight-loss drugs like Ozempic and Wegovy can dramatically curb appetite, but experts warn many users are flying blind when it comes to nutrition. New

Sunday, March 29, 2026 – Could weight-loss drugs shrink the body representation we’ve spent decades seeking?

Sunday, March 29, 2026 – Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price,

Sunday, March 29, 2026 – INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating

Sunday, March 29, 2026 – South San Francisco, CA — March 5, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline

Sunday, March 29, 2026 – Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026 – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers

Sunday, March 29, 2026 – NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its

Sunday, March 29, 2026 – (MedPage Today) — The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide

Sunday, March 29, 2026 – A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It’s a simple premise: What if something as

Sunday, March 29, 2026 – (MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes,

Sunday, March 29, 2026 – (MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its

Sunday, March 29, 2026 – (MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an

Sunday, March 29, 2026 – Shanghai Unixell Biotechnology Co. Ltd. has obtained IND clearance from the FDA for UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy. A phase I

Sunday, March 29, 2026 – (MedPage Today) — Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume (RGV) if the medication wasn’t held prior to upper endoscopy unless

Sunday, March 29, 2026 – (MedPage Today) — For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their

Sunday, March 29, 2026 – The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay

Sunday, March 29, 2026 – Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy

Sunday, March 29, 2026 – Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults

Sunday, March 29, 2026 – The study findings may spark treatment innovations for depression and anxiety.

Sunday, March 29, 2026 – GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a

Sunday, March 29, 2026 – In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to

Sunday, March 29, 2026 – INDIANAPOLIS, March 19, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating

Sunday, March 29, 2026 – (MedPage Today) — The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on

Sunday, March 29, 2026 – A stronger version of the popular weight loss drug Wegovy is on the way after federal regulators signed off on a higher dose. The U.S.

Sunday, March 29, 2026 – Whether they’re using weekly shots or daily pills, more Americans than ever are turning to anti-obesity drugs to lose weight and boost health.

Sunday, March 29, 2026 – This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo

Sunday, March 29, 2026 – WEDNESDAY, March 25, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, are associated with a reduced risk for worsening of anxiety and depression that

Sunday, March 29, 2026 – In new research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May), a global panel of 21 obesity and

Sunday, March 29, 2026 – A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available counterparts, according to a

Sunday, March 29, 2026 – So you’ve decided to go on a GLP-1 to lose weight. These medicines might seem like an easy way to drop unwanted pounds, but you’ll